难治性硬皮病并发溃疡性结肠炎的双重生物治疗。

Hae Chan Lee, Yiyoung Kwon, Eun Sil Kim, Soomin Ahn, Yon Ho Choe, Mi Jin Kim
{"title":"难治性硬皮病并发溃疡性结肠炎的双重生物治疗。","authors":"Hae Chan Lee,&nbsp;Yiyoung Kwon,&nbsp;Eun Sil Kim,&nbsp;Soomin Ahn,&nbsp;Yon Ho Choe,&nbsp;Mi Jin Kim","doi":"10.5021/ad.21.060","DOIUrl":null,"url":null,"abstract":"<p><p>Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug's mechanism of action.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"35 Suppl 1","pages":"S107-S111"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/d0/ad-35-S107.PMC10608359.pdf","citationCount":"0","resultStr":"{\"title\":\"Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum.\",\"authors\":\"Hae Chan Lee,&nbsp;Yiyoung Kwon,&nbsp;Eun Sil Kim,&nbsp;Soomin Ahn,&nbsp;Yon Ho Choe,&nbsp;Mi Jin Kim\",\"doi\":\"10.5021/ad.21.060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug's mechanism of action.</p>\",\"PeriodicalId\":94298,\"journal\":{\"name\":\"Annals of dermatology\",\"volume\":\"35 Suppl 1\",\"pages\":\"S107-S111\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/d0/ad-35-S107.PMC10608359.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5021/ad.21.060\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5021/ad.21.060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

坏疽性脓皮病是溃疡性结肠炎(UC)的一种肠道外皮肤病表现。我们报告了一例26岁男性患者,患有复发性UC,并伴有新发的坏疽性脓皮病。他的皮肤和肠道症状难以用类固醇、免疫抑制剂或单一生物制剂(如英夫利昔单抗、戈利木单抗或维多利珠单抗)治疗。我们在韩国首次报道了使用维多利珠单抗和英夫利昔单抗双重生物制剂成功治疗UC坏疽性脓皮病的经验。我们战略性地针对每一种肠道和皮肤症状,使用基于药物作用机制的特定生物制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum.

Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum.

Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum.

Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum.

Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug's mechanism of action.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信